行情

NURO

NURO

NeuroMetrix
NASDAQ

实时行情|Nasdaq Last Sale

1.520
+0.384
+33.78%
盘后: 1.530 +0.01 +0.66% 19:53 04/01 EDT
开盘
1.220
昨收
1.136
最高
2.070
最低
1.210
成交量
199.88万
成交额
--
52周最高
11.10
52周最低
0.8120
市值
220.74万
市盈率(TTM)
-0.3338
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NURO价格均价为50.00,最高价位50.00,最低价为50.00。

EPS

NURO 新闻

更多
  • 全球避孕套告急!泰国最大生产商达到产能极限
  • 新浪财经 · 52分钟前
  • 油价大涨 伦敦布伦特油价涨幅扩大至近13%
  • 新浪财经 · 1小时前
  • 美服装巨头PVH的老板戏剧性确诊感染新冠:无症状
  • 新浪财经 · 1小时前
  • 高盛:垃圾债最坏的日子尚未到来 违约势将增加
  • 新浪财经 · 1小时前

所属板块

医疗设备、用品及经销
-4.79%
医疗设备和用品
-4.98%

热门股票

代码
价格
涨跌幅

NURO 简况

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.
展开

微牛提供Neurometrix Inc(NASDAQ-NURO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NURO股票新闻,以帮助您做出投资决策。